
    
      This is a Phase 1, open-label, randomized, 2-sequence, 3-period crossover study evaluating
      the relative bioavailability of TAS-102 tablets compared to an oral solution in patients with
      advanced solid tumors. This study will be conducted in 2 parts. The crossover bioavailability
      part will be followed by an extension conducted with TAS-102 tablets only.
    
  